Brief: Biofrontera announces sale of license to Xepi Antibiotic Cream to Pelthos Therapeutics for up to $10 Million
07/11/2025 13:11
Nov 7 (Reuters) - Biofrontera Inc BFRI.O: BIOFRONTERA INC. ANNOUNCES SALE OF LICENSE TO XEPI® ANTIBIOTIC CREAM TO PELTHOS THERAPEUTICS INC. FOR UP TO $10M BIOFRONTERA INC - DEAL EXPECTED TO FUND BIOFRONTERA TO PROFITABILITY Source text: ID:nGNXc0jXQj Further company coverage: BFRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales